Committee Blog: 13 Women Cannabis Scientists to Follow and Support

by Russ Hudson, Canna Advisors
Member of NCIA’s Scientific Advisory Committee

Introduction

These 13 women cannabis scientists and researchers deserve to be recognized for their significant scientific and academic merit alone, irrespective of their gender. For now, we are identifying these stellar individuals as women solely because of the cannabis industry’s longstanding domination by males. Supporting these professionals in their scientific work with cannabis is critical to advancing the global cannabis agenda, which seeks to make cannabis medicine and other products readily available to people globally. Sharing the work and efforts of these exceptional humans is precisely what is needed to inspire the next generation of cannabis scientists, where gender will no longer be a defining feature.        

Shawna Vreeke, Ph.D.

*Ph.D. in Organic Chemistry from Portland State University
*Cannabis Toxicology and Risk Assessment

Dr. Vreeke works with Ethan Russo and the team at True Terpenes, where she is Head of Research, performing risk assessments and managing the company’s toxicology program that she developed. With nearly a decade of experience already in laboratory research, Dr. Vreeke is expected to have a long and storied career in the science of cannabis.  

PUBLICATIONS BY SHAWNA VREEKE, Ph.D.:

A First-Tier Framework for Assessing Toxicological Risk from Vaporized Cannabis Concentrates

A Simple Predictive Model for Estimating Relative E-cigarette Toxic Carbonyl Levels

Dihydroxyacetone levels in electronic cigarettes: Wick temperature and toxin formation. 

E-cigarettes can emit formaldehyde at high levels under conditions that have been reported to be non-averse to users

Triacetin Enhances Levels of Acrolein, Formaldehyde Hemiacetals, and Acetaldehyde in Electronic Cigarette Aerosols

 

Susan Trapp, Ph.D.

*Ph.D. in Biochemistry from the University of Maryland
*Cannabis terpene researcher

Dr. Trapp is one of the world’s leading terpene experts, and she also happens to be an expert in cannabis, particularly where related to the plant’s chemical constituents. Dr. Trapp is the Senior Research Scientist for the Southwest College of Naturopathic Medicine & Health Sciences, she is the co-founder and chief scientist of a terpene company she founded called Terpedia, and she is an adjunct biology professor at Red Rocks Community College in Lakewood, Colorado. Dr. Trapp contributed commentary to The Big Book of Terps, and has authored the publications listed below:

PUBLICATIONS BY SUSAN TRAPP, Ph.D.:

Genomic Organization of Plant Terpene Synthases and Molecular Evolutionary Implications

Defensive Resin Biosynthesis in Conifers

Draft genome sequence of Mentha longifolia and development of resources for mint cultivar improvement

Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma

Molecular signatures of neoadjuvant endocrine therapies for breast cancer: characteristics of response or intrinsic resistance, Breast Cancer Research and Treatment

 

Riley Kirk, Ph.D.

*Ph.D. in Pharmaceutical Sciences from University of Rhode Island
*Cannabis educator and research scientist

Dr. Kirk is a natural product chemist working as a Cannabis Research Scientist for Real Isolates, LLC. She is also a cannabis science educator for Cannabichem, LLC, and has spent years donating her time to various worthy charitable causes and programs. 

PUBLICATIONS BY RILEY KIRK, Ph.D.:

Screening the PRISM Library against Staphylococcus aureus Reveals a Sesquiterpene Lactone from Liriodendron tulipifera with Inhibitory Activity

New Micropeptins with Anti-Neuroinflammatory Activity Isolated from a Cyanobacterial Bloom

Polyphenol Microbial Metabolites Exhibit Gut and Blood–Brain Barrier Permeability and Protect Murine Microglia against LPS-Induced Inflammation

 

Daniela Vergara, Ph.D.

*Ph.D. in Evolutionary Biology from Indiana University Bloomington
*Cannabis researcher: genomics, breeding

A long-time dedicated researcher in the higher education industry, Dr. Vergara is currently an emerging crop specialist for Cornell University, a research associate with the University of Colorado Boulder, and the director and founder of the Agricultural Genomics Foundation based in Colorado. 

PUBLICATIONS BY DANIELA VERGARA, Ph.D.:

Widely assumed phenotypic associations in Cannabis sativa lack a shared genetic basis

 

Anna Schwabe, Ph.D.

*Ph.D. in Biological Education from University of Northern Colorado
*Cannabis educator and R&D specialist
*Cannabis genetics

Dr. Schwabe is a cannabis geneticist with a passion for studying inconsistencies in commercially available cannabis flower. Extremely active in the cannabis space and beyond, Dr. Schwabe is the Director of Cannabis Education for 420 Organics, the Director of Research and Development for Shore Organics, and an Associate Lecture Professor for the University of Colorado Boulder. 

PUBLICATIONS BY ANNA SCHWABE, Ph.D.:

Comparative Genetic Structure of Cannabis sativa Including Federally Produced, Wild Collected, and Cultivated Samples

Genomic Evidence That Governmentally Produced Cannabis sativa Poorly Represents Genetic Variation Available in State Markets

Research grade marijuana supplied by the National Institute on Drug Abuse is genetically divergent from commercially available Cannabis

Genetic tools weed out misconceptions of strain reliability in Cannabis sativa: Implications for a budding industry

Weeding out the truth behind Cannabis strain names: Genetic analyses confirm strain names are inconsistent and need regulation

 

Megan Mbengue

*Master of Science in Medical Cannabis Therapeutics from Pacific College
*Cannabis Nurse – CHPN, RN

Megan Mbengue, BSN, RN, CHPN is the founder of Trusted Cannabis Nurse, and has earned her reputation as a frank and passionate consumer educator in the cannabis industry. A longtime RN specializing in hospice and palliative care, Megan brings her passion for cannabis science education to the public, supported by a line of her own high quality hemp extract products.  

 

Jill Carreiro

*BS, Bioengineering, Arizona State University
*Cannabis analytical testing expert

Jill specializes in cannabis analytical chemistry, working as Vice President of Sales for Orange Photonics, a company that produces analytical testing equipment for the cannabis industry – most notably handheld and portable testing units. Jill has a strong scientific background in analytical instrumentation, supported by her education in bioengineering. 

 

Shabnam Sarshar, Ph.D.

*Ph.D. in Pharmaceutical Biology and Phytochemistry from University of Munster
*Cannabis phytochemical researcher

Dr. Sarshar is passionate about cannabis for women’s health, having founded Laia’s FemBalance, a company that advocates for and encourages women’s health and other rights in Germany and worldwide. With an MBA in addition to a Ph.D., Dr. Sarshar is also a proficient and well-known business expert.  

PUBLICATIONS BY SHABNAM SARSHAR, Ph.D.:

Plants of the Gods and Their Recently Discovered Therapeutic Applications.

Traditionally used medicinal plants against uncomplicated urinary tract infections: Hexadecyl coumaric acid ester from the rhizomes of Agropyron repens (L.) P. Beauv. with antiadhesive activity against uropathogenic E. coli.

 

Allyn Howlett, Ph.D.

*Ph.D. in Biochemical Neuropharmacology from Rutgers University
*Professor at Wake Forest University Baptist Medical Center
*Discoverer of CB1 receptor for cannabinoid agonists

Dr. Howlett is one of the most-published cannabis-specific scientists in the world, and comes highly recommended to this list by numerous well-respected cannabis scientists and researchers. Dr. Howlett is also a Professor of Physiology and Pharmacology at Wake Forest University Baptist Medical Center, where her expertise as a biochemical neuropharmacologist working with cannabinoid receptor signal transduction is highly valued by the current and next generation of cannabis and other professionals. 

PUBLICATIONS BY ALLYN HOWLETT, Ph.D.:

Increased Angiotensin II Contraction of the Uterine Artery at Early Gestation in a Transgenic Model of Hypertensive Pregnancy Is Reduced by Inhibition of Endocannabinoid Hydrolysis

Alterations in the Medullary Endocannabinoid System Contribute to Age-related Impairment of Baroreflex Sensitivity

Is there a role for anandamide in cardiovascular regulation? Insights from studies of endocannabinoid metabolism

Steric Trigger as a Mechanism for CB1 Cannabinoid Receptor Activation

Early phytocannabinoid chemistry to endocannabinoids and beyond

WIN55212-2 Docking to the CB1 Cannabinoid Receptor and Multiple Pathways for Conformational Induction

Endocannabinoid System in Pregnancy Maintenance and Labor: A Mini-Review

Endocannabinoids and Reactive Nitrogen and Oxygen Species in Neuropathologies

Cannabinoid Receptor Interacting Protein 1a (CRIP1a) in Health and Disease

Acute Depletion of D2 Receptors from the Rat Substantia Nigra Alters Dopamine Kinetics in the Dorsal Striatum and Drug Responsivity

The Spicy Story of Cannabimimetic Indoles

The Endocannabinoid System and Oligodendrocytes in Health and Disease

Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure

WIN55212-2 Modulates Intracellular Calcium via CB1 Receptor-Dependent and Independent Mechanisms in Neuroblastoma Cells

Cannabinoid receptor interacting protein 1a interacts with myristoylated Gαi N terminus via a unique gapped β-barrel structure

CB1 Cannabinoid Receptors Stimulate Gβγ-GRK2-Mediated FAK Phosphorylation at Tyrosine 925 to Regulate ERK Activation Involving Neuronal Focal Adhesions

Thyroid Effects on Adenosine 3′,5′-Monophosphate Levels and Adenylate Cyclase in Cultured Neuroblastoma Cells

Medullary Endocannabinoids Contribute to the Differential Resting Baroreflex Sensitivity in Rats with Altered Brain Renin-Angiotensin System Expression

 

Ziva Cooper, Ph.D. 

*Ph.D. in Biopsychology from the University of Michigan
*Director of the UCLA Center for Cannabis and Cannabinoids

Dr. Cooper is the Director of the UCLA Center for Cannabis and Cannabinoids, and Associate Professor in the Department of Psychiatry and Biobehavioral Sciences. A longtime health care professional specializing in neurobiology, Dr. Cooper has been working in the cannabis industry for many years, including a former appointment on the Committee on the Health Effects of Marijuana by The National Academies of Sciences, Engineering, and Medicine. Dr. Cooper has published numerous studies on various aspects of cannabis and cannabinoids. 

PUBLICATIONS BY ZIVA COOPER, Ph.D.:

Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability

Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073

Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective

Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers

The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research

Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.

Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis.

Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal

Novel Pharmacologic Approaches to Treating Cannabis Use Disorder

Investigation of sex-dependent effects of cannabis in daily cannabis smokers

A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers

Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers.

Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts.

Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers

Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.

Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Marijuana’s dose-dependent effects in daily marijuana smokers.

Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.

Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status.

Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques.

Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances

Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.

Opioid antagonism enhances marijuana’s effects in heavy marijuana smokers.

Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts

Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.

Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.

Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers.

Sex-dependent effects of cannabis-induced analgesia

 

Carrie Cuttler, Ph.D.

*Ph.D. in Cognitive Science from the University of British Columbia 

Dr. Cuttler has published many valuable, relevant studies on cannabis and its constituents, especially in the field of obsessive use and addictive consumption, where her extensive education in psychiatry serves her and the public well. Dr. Cuttler is also an Assistant Professor with Concordia University.  

PUBLICATIONS BY CARRIE CUTTLER, Ph.D.:

Blunted stress reactivity in chronic cannabis users

Psychometric properties of the Daily Sessions, Frequency, Age of Onset, and Quantity of Cannabis Use Inventory (DFAQ-CU)

Symptoms of obsessive-compulsive disorder predict cannabis misuse

A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy

Sex differences in cannabis use and effects: A cross-sectional survey of cannabis users

Mechanisms underlying the link between cannabis use and prospective memory

 

Michelle Glass, Ph.D.

*Head of the Department of Pharmacology & Toxicology at the University of Otago

Dr. Glass has specialized in cannabis, researching, among other subjects, cannabinoids, neurodegenerative diseases, Huntington’s disease, and G-protein coupled receptors. According to her profile on The University of Octago, “Professor Glass’ research focuses on the expression, function and molecular pharmacology of the cannabinoid receptors and their potential role in treatment of neurodegenerative diseases. Her recent research interests have extended to identifying the mechanism by which synthetic cannabinoids are resulting in high levels of toxicity in the community and advising on the development of clinical trials for medicinal cannabis products.”

PUBLICATIONS BY MICHELLE GLASS, Ph.D.:

Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain

Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor

Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor.

The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington’s diseas

Cannabinoid receptors and their endogenous agonists

Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor crosstalk?

Synthetic cannabis: adverse events reported to the New Zealand Pharmacovigilance Centre

Receptor alterations in human neuro-degenerative diseases

 

Amber Wise, Ph.D.

*Ph.D. in Chemistry from the University of California at Berkeley
*Cannabis compliance and analytical testing expert

Dr. Wise is an analytical chemist and laboratory manager with extensive experience at multiple universities. The current Scientific Director for Medicine Creek Analytics as well as the Programming Chair for the Cannabis Chemistry Subdivision of ACS, Dr. Wise has published several studies on the aerosols of cannabis products and byproducts of cannabis extractions, as well as studies in other fields.  

PUBLICATIONS BY AMBER WISE, Ph.D.

Metals in Cannabis Vaporizer Aerosols: Sources, Possible Mechanisms, and Exposure Profiles

Strategies for Nonpolar Aerosol Collection and Heavy Metals Analysis of Inhaled Cannabis Products

Deeper Dive into Extractions: Multiphase CO2 Extractions for Full Spectrum Native Chemical Profiles

Understanding the Science of Cannabis Produce DevelopmentExtraction Basics, Scientifically Speaking

Upstream adverse effects in risk assessment: A model of polychlorinated biphenyls, thyroid hormone disruption and neurological outcomes in humans.

Are Oral Contraceptives Significant Contributors to Estrogenicity of Drinking Water?

Discrete Arrays of Liquid Crystal-Supported Proteolipid Monolayers as Phantom Cell Surfaces

Policy Recommendations for Addressing Potential Health Risks from Nanomaterials in Californi

Are there other cannabis scientists that should be included in this list? Let us know using the CONTACT FORM HERE, or connect with the author via LinkedIn: https://www.linkedin.com/in/russhudson/

 

Member Blog: Are Women In Cannabis Facing Some Headwinds?

By Maureen Ryan, Kukuza Associates

So far, the cannabis industry is willing to elevate female executives more than other industries. And it’s been this way since adult-use legalization started to spread among states in 2014. That’s when a huge opportunity opened up for people with some leadership experience and a cool idea. Women who had hit a glass ceiling in more traditional industries saw a chance to make a rewarding career shift. Long-term success isn’t a given for anyone making this move, but it’s easier to get in and get noticed if you have a niche product, a specialized service, or fill a particular wellness need. 

I fear the inroads women have made for higher ranks at canna companies are getting needlessly tougher. As our industry continues to mature and expand, larger amounts of funds are needed to get a business off the ground or scale a business, but securing funds could become harder if you’re female. 

From the moment I first started helping cannabis companies, I was riveted by its diversity and inclusion. In my years of working with some of the most innovative companies in Silicon Valley, I was used to male-dominated cultures. It didn’t matter what I role I held — I started as an engineer in aerospace and later became involved in operations, marketing and sales, and professional services — a lopsided imbalance was often in play. 

But with cannabis, this industry has seen a higher proportion of women rise to great heights. More than one-third of executives at cannabis companies are female. That’s remarkable when you also take into account that females hold only 21 percent of senior-level roles at other types of companies, according to Marijuana Business Daily survey figures. On a more anecdotal level, however, I suspect from what I’m hearing that the gains women have made could waver. With industry maturity, even at this early stage, comes the zealous interest of deeply pocketed investors (most of them men).

Why the Shift?

Female leaders in cannabis have made great strides, but history threatens to repeat itself. For instance, this statistic would make anyone wince: Female founders across all industries acquired only 2.2 percent of venture capital in 2018, according to PitchBook. And those who are able to get the funding they need don’t get as much as men in the same position. 

We’re in the midst of rapid growth, and big-name investors are noticing. While I don’t want to generalize, it’s widely known that investors are more likely to be white males. This puts the more equitable playing field created by cannabis at risk. 

In some ways, it’s natural that as more money comes in, there would be a shift. That’s the tradition, as more men have traditionally been dominant in business. I don’t buy into this tradition and it’s what attracted me to the industry — the cannabis industry is known for being non-traditional. We’ve been cracking glass ceilings and we’ve been shedding corporate conventions. The result has been fast growth, satisfied customers, and innovative products. I think we can attribute some of that to the diversity at work. 

How can we ensure that women get their fair share? There are loads of opportunities here for entrepreneurs and seasoned executives, across genders, to make their mark. What matters less than someone’s gender is the ideas they have, their plan for making their business thrive, and whether they have a solid foundation for truly understanding the company as they make big decisions. When you encounter women entrepreneurs, I encourage everyone to give them a shot, hear out the business plan, and assess the opportunity they’re presenting with an open mind. 

There is still time to build upon the momentum women have made. Let’s all, especially men and investors, make a concerted effort to fully support women-led businesses and recognize the need for diverse talents and skillsets. I made a similar call in a blog post for my firm, and I was pleased with the reaction — it really hit a nerve. Women in our industry clearly want to talk about this. The consensus is that when different perspectives are voiced, smart ideas and decisions rise to the top. 


As vice president, Maureen Ryan leads the business development functions at Kukuza Associates, a finance and accounting firm dedicated to the needs of cannabis companies. She spearheaded Kukuza’s parent company’s (RoseRyan) 2014 entrance into the cannabis marketplace and developed Kukuza’s finance solution to address the common pain points across cannabis companies. Check out the Kukuza Rapid Diagnostic to find out if you have the right finance pieces in place to scale your business.

 

How to improve profitability with infused marijuana products: Tips from a cannabis industry veteran

By Christie Lunsford, 3D Cannabis Center

Legal cannabis markets in the US are expected to grow over 60% in 2014. Currently, infused goods comprise 50% of the total market, with the fastest market growth happening in concentrates over the next year. How is your state-legal adult-use marijuana store or medical cannabis dispensary educating employees and consumers about the fastest growing sector in the cannabis marketplace?

It’s the dreaded scenario all cannabis enthusiasts experience – they want to try an edible, drink, or concentrate and have no idea how they work or what kind of an effect it will have on them. Having a staff knowledgeable about different cannabinoid delivery systems will help your team build sales and develop a loyal customer base. Here’s the basic cannabis uptake information every cannabusiness person needs to know to be effective in sales or advocacy.

Oral mucosal (soft tissues of the mouth) delivery systems are the most effective and efficient way to deliver the effects of THC and other constituents to consumers. Products including tinctures, mints, hard candies, and oral transfer film (OTF) all offer a quick onset head high with slight sedative effects.

Concentrates are the hottest cannabis trend in the combustible market and account for a large share of the growth in the infused products sector. Including CO2, butane extraction, and water hash, concentrates take the form of wax, shatter, glass, and hash and are consumed in a vape pen or combustion device. The uptake is very quick and the effects are easily prolonged by inhaling small amounts.

Edibles account for approximately 30% of the current infused market. A consumer favorite, edibles have slower onset and longer lasting psychoactive effect. Edibles take longer to show their effects because they are broken down by the stomach. Then the THC is transformed into delta 9 and passed into the blood stream via the liver. Some examples of edibles include THC-infused drinks like Dixie Elixirs sparkling beverages, chocolates, cookies, confections, and capsules. Capsules are a welcome and growing trend in the edible delivery format with a more palatable look and feel for the expanding medical cannabis markets.

Topical delivery systems are the most approachable to use, offering localized pain relief and no psychotropic effect. Simply rub on or in the case of Dixie Bath Soak, soak up the relief. Cannabis topicals are a great way to introduce cannabis products to elders and those who don’t have a deep relationship with the plant.

Understanding alternate cannabinoid delivery systems and how infused products work with each can help you and your staff offer better customer service, encouraging repeat customer business and strengthening your store’s bottom line. Always work with a reputable infusion company that offers additional services like cannabis education and will be a partner to your store’s long-term success.

Christie Lunsford is Director of Operations at 3D Cannabis Center and a cannabis industry veteran. As a board member of the Women’s CannaBusiness Network, a project of the National Cannabis Industry Association, she has worked to lobby Congress in the areas of fair taxation and banking laws for state-legal medical marijuana businesses. You can follow her cannabis industry exploits via Cannapodcast.

Medical Cannabis Businesswomen Call on President Obama to Freeze Enforcement Actions While Reviewing Administration’s Medical Marijuana Policy

Washington, DC — The National Cannabis Industry Association (NCIA), in conjunction with the Women’s CannaBusiness Network, a project it launched earlier this year, today called on President Obama to cease enforcement actions against state-legal medical cannabis providers while the administration reviews its policies to determine whether they are in the public interest. Respected industry businesswomen defended their work and powerfully expressed their frustration with the administration’s crackdown.

“The women here today are compassionate and courageous leaders,” said Jill Lamoureaux , owner of Colorado Dispensary Services. “They are pioneers in alternative medicine. They are job creators and tax revenue generators. They are hear to bring awareness to the Obama administration’s reversal on medical marijuana policy and to ask that the Justice Department immediately stop shutting down state-legal businesses that are serving patients, creating jobs and generating tax revenues.”

Jen Reynolds , a mother of four who will lose her job on Monday because of the actions of the U.S. attorney in Colorado, urged the President to think about the people whom are being affected.

“This is not about ‘marijuana dealers,'” Reynolds said. “This is about medical cannabis patients having a safe and regulated environment in which to purchase their medicine. It is about employees like me, who had the amazing opportunity to help patients alleviate their suffering, while earning a living wage. My center should have been a model for others to follow, not a target for federal action.”

NCIA also released a report entitled, “The Colorado Cannabis Industry: A Tale of Ten Cities,” which details the sales and tax revenues generated by medical marijuana centers in ten Colorado cities.

“The ten cities included in the report alone generated close to $10 million in state and local sales taxes in 2011,” explained Aaron Smith , NCIA executive director. “This money is being used to improve government services in these areas, which is one more benefit of a regulated medical cannabis industry.”

 

This site uses cookies. By using this site or closing this notice, you agree to the use of cookies and our privacy policy.